> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Trump Signs Executive Order to Accelerate Psychedelic Therapies
- URL: https://www.fdaweb.com/trump-signs-executive-order-to-accelerate-psychedelic-therapies/
- Published: 2026-04-20T12:00:00.000Z
- Updated: 2026-09-14T13:37:41.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5161007

President Trump has signed a sweeping [executive order](https://www.whitehouse.gov/fact-sheets/2026/04/fact-sheet-president-donald-j-trump-is-accelerating-medical-treatments-for-serious-mental-illness/?ref=fdaweb.com) aimed at accelerating the development and availability of psychedelic-based treatments for patients with serious mental illness, directing federal agencies to streamline regulatory pathways, expand research funding, and improve patient access to investigational therapies.

The order places significant new responsibilities on FDA and the Drug Enforcement Administration (DEA), including the use of the Commissioner’s National Priority Vouchers for certain psychedelic drugs that have already received a breakthrough therapy designation. The move is intended to expedite regulatory review timelines for therapies targeting conditions such as treatment-resistant depression and post-traumatic stress disorder.

Under the directive, FDA and DEA must also establish a pathway for eligible patients to access investigational psychedelic compounds — including ibogaine — under the framework of the Right to Try Act, which allows patients with serious or life-threatening conditions to seek experimental treatments outside of clinical trials.

The executive order calls on HHS to allocate $50 million through the Advanced Research Projects Agency for Health to support state-level psychedelic research initiatives, effectively matching local investments to accelerate development programs.

Federal agencies are also directed to work with the U.S. Department of Veterans Affairs and private-sector partners to expand clinical trial participation and strengthen evidence generation for experimental therapies. In parallel, the order instructs the U.S. attorney general to begin reviewing the scheduling status of relevant substances following successful Phase 3 trials, with the goal of enabling faster rescheduling upon FDA approval.

The White House framed the policy as a response to persistent gaps in treating serious mental illness, particularly among military veterans. According to the administration, more than 14 million U.S. adults live with serious mental illness, with millions relying on existing medications that may not be effective for all patients.